Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma

The clinical utilities of paclitaxel in anaplastic thyroid carcinoma (ATC) have been reported. The current study investigated the outcomes in ATC patients treated by paclitaxel as neoadjuvant setting. Furthermore, the prognostic factor for overall survival (OS) and predictive marker for response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Haruhiko, Sugino, Kiminori, Katoh, Ryohei, Matsuzu, Kenichi, Masaki, Chie, Akaishi, Junko, Hames, Kiyomi Yamada, Tomoda, Chisato, Suzuki, Akifumi, Ohkuwa, Keiko, Kitagawa, Wataru, Nagahama, Mitsuji, Rino, Yasushi, Ito, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939216/
https://www.ncbi.nlm.nih.gov/pubmed/36052510
http://dx.doi.org/10.1002/cam4.5219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939216/
https://www.ncbi.nlm.nih.gov/pubmed/36052510
http://dx.doi.org/10.1002/cam4.5219

Ejemplares similares